MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program
Zijun Y. Xu-Monette, Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, Lei Fan, Carlo Visco, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W L Choi, J. Han van Krieken, Qin Huang, Jooryung HuhWeiyun Ai, Maurilio Ponzoni, Andrés J M Ferreri, Lin Wu, Xiaoying Zhao, Carlos E. Bueso-Ramos, S. A. Wang, Ronald S. Go, Yong Li, Jane N. Winter, Miguel A. Piris*, L. Jeffrey Medeiros, Ken H. Young
Dive into the research topics of 'MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program'. Together they form a unique fingerprint.